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Abstract
Objective: This study sought to determine whether relationships exist between stimulant medications and children’s growth velocity. 
Methods: The investigators conducted a retrospective review of 280 charts of pre-pubertal children with attention-deficit hyperactivity 
disorder (ADHD) who were prescribed stimulant medications for a minimum of 1 year. The children were patients in a university child 
development/ADHD clinic. Results: The average growth velocity across all genders and ages was 5.72 cm/year (females 5.53 cm/year, 
males 5.28 cm/year). The majority of the children had growth velocities in the 25-50th percentiles for age. Conclusion: This study did 
not find evidence of significant effect on growth velocity in children with ADHD treated with stimulant medications. Our results concur 
with the majority of other studies of growth in children taking stimulant medications for ADHD management. It supports our continued 
prescription of stimulant medications without concern for slowed or stunted growth in our patients with ADHD.
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Approximately 3-7% of all children are affected by attention-deficit hyperactivity disorder (ADHD) [1]. Stimulant medications frequently are prescribed to 
manage ADHD symptoms in children and adolescents. These 
medications improve the core symptoms of inattention, 
impulsivity, and hyperactivity [2]. Other problem behaviors, 
such as noncompliance with instructions, impulsive aggression, 
poor social interactions, academic performance, and family 
dynamics, also may improve with stimulant medications [3]. 
The multimodal treatment study of 600 children with ADHD 
compared the efficacy of four treatment modes (medications, 
behavior therapy, medications plus behavior therapy, and 
community care) in reducing ADHD symptoms. The study 
found that the responses of the children in two arms of the study 
(medication combined with behavior therapy and medication 
alone) were superior to intensive behavior therapy alone and to 
routine community care [4].
There are two major families of stimulant medications 
(methylphenidates, amphetamines) used to treat ADHD. Non-
stimulant medications (alpha agonists, selective non-reuptake 
releasing inhibitors, antidepressants) are also prescribed, 
usually as adjuncts to stimulant medications [5-7]. Stimulants 
are commonly the first line of treatment, because they are well-
tolerated, become effective quickly, and are rapidly eliminated 
from the body. Methylphenidate and dextroamphetamine 
preparations are equally effective [8]. Children may respond 
to one stimulant, but not to another. Therefore, finding the 
right stimulant medication for a child is often a practice of 
trial and error. Stimulant dosages vary, based on tolerance 
of the compound, not body weight. Common side-effects of 
stimulants are appetite suppression and sleep disturbance, both 
of which can be dose-dependent [9]. Some children experience 
transient abdominal pain, headache, or a mild increase in 
heart rate and blood pressure. Less common side effects of 
stimulant medications are irritability, nervousness or jitteriness. 
Children on high dosages or those who are very medication 
sensitive may experience mental “dulling,” mood disturbances, 
psychotic reactions, or being “over focused.” Motor tics and 
rebound hyperactivity are not uncommon.
Although these medications are generally well-tolerated, 
questions have been raised about the effects of stimulant 
medications on children’s growth velocity. Researchers have 
postulated that stimulants may adversely affect growth by their 
anorexic effect and by an increase in synaptic dopamine, which 
causes acute inhibition in growth hormone [10,11]. Poulton 
conducted an extensive review of published reports on growth 
concerns and ADHD treatment. He cited “clear evidence of 
an association between treatment with stimulant medication 
and attenuated growth in height in the better quality studies,” 
although he did note methodological shortcomings in several 
studies [12]. In 1998, Spencer et al. proposed that differences 
in growth velocity could be attributed to ADHD itself, 
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rather than to the stimulant medications taken to manage the 
condition [13]. Ten years later, two researchers reported growth 
suppression in children with ADHD ages 9-14 years and also 
attributed the effect to the condition of ADHD itself rather than 
to its treatment with stimulant medications [14]. Biederman 
et al. found no significant difference in peak height velocity 
between stimulant-treated and stimulant-naïve children with 
ADHD [15]. An article published in the latter part of 2014 
reported that a longitudinal, population-based study showed 
that neither childhood ADHD itself or stimulant treatment was 
associated with significant height deficits into adulthood [16].
Study Objective
This study was designed to contribute to the literature on growth 
in children with ADHD using a less common methodology, a 
retrospective chart review. The study objective was to determine 
whether relationships exist between stimulant medications and 
children’s growth velocity. The data used were measurements of 
children whose stimulant medication regimens were consistent 
with commonly accepted treatment recommendations.
METHODS
Members of the research team conducted 280 chart reviews 
of pre-pubertal children who were prescribed stimulant 
medications for at least 1 year. These children had been 
diagnosed with ADHD using the standard diagnostic criteria 
established and published by the American Psychiatric 
Association in the Diagnostic and Statistical Manual of Mental 
Disorders, Fourth Edition [17] and from positive parent and 
teacher responses on standardized ADHD questionnaires. Most 
of the children were enrolled at age 4 years as new patients and 
began taking stimulants at the time of enrollment. None of the 
children took stimulant medications before age 4 years.
We excluded children with ADHD who were not taking 
stimulant medications, those who had fewer than two visits 
6 months apart, and those who took medication holidays 
between the clinic visits. Female subjects who achieved 
menarche, children taking growth hormone injections, those 
with genetic syndromes, and those with other growth-limiting 
conditions (e.g., cerebral palsy) also were excluded.
The children’s stimulant medications included both short-
acting and long-acting amphetamine and methylphenidate 
preparations. Children were prescribed the lowest dosages that 
achieved adequate control of their ADHD symptoms.
We used height and weight measurements collected at clinic 
visits to calculate growth velocity and then compared these data 
to normed growth velocity for the general pediatric population. 
At each clinic visit, children’s heights were measured upright, 
minus shoes, using a stadiometer. Weights were obtained using 
an approved clinic scale. The stadiometer and scale were 
calibrated on a regularly scheduled basis. Children’s heights 
and weights were plotted on standard growth charts provided by 
the United States Centers for Disease Control and Prevention 
(CDC) [18]. The CDC growth charts are a national reference 
representing how US children and adolescents grew during the 
1970s, 1980s and 1990s. The CDC recommends using these 
references from ages 2 through 19 years to track weight, stature, 
and body mass index from childhood through age 19 years. We 
used these charts to represent the growth of the general pediatric 
population (Figures 1 and 2). Growth velocities were calculated 
using the charts from the Fels Longitudinal Study [19]. Our 
study was approved by the University Institutional Review 
Board.
RESULTS
The children were ages 4-15 years (mean = 8.92; standard 
deviation = 2.52). The majority (78%) of the children were 
males. Descriptive statistics (frequencies, measures of 
central tendency) were used to analyze the growth data. The 
average growth velocity across all ages and genders was 
5.72 cm/year. Females averaged 5.53 cm/year and males 
5.28 cm/year. Among the females, the greatest growth velocity 
(6.20 cm/year) was observed between 9 and 10 years of age. 
Among the males, the greatest growth velocity (6.65 cm/year) 
was observed at 15 years of age. Of the 280 children in the 
study, the majority achieved annual growth velocities at or 
above the 10th percentile for age.
DISCUSSION
We did not find evidence of a significant effect on growth 
velocity in children treated with stimulant medications. The 
average growth velocity within each gender and across all ages 
was comparable to the general pediatric population (Table 1). 
Table 1: Study participant average semi-annual growth 
velocity (rounded age and sex)
Age Sex (SD)
Male (n=218) Female (n=62)
4 3.04 (0.49) 2.95 (1.27)
5 2.95 (0.43) 2.60 (0.56)
6 2.68 (0.62) 2.54 (0.50)
7 2.51 (0.70) 2.85 (1.04)
8 2.06 (0.67) 2.37 (0.76)
9 2.69 (0.75) 2.66 (1.37)
10 2.42 (0.53) 2.76 (0.85)
11 2.68 (0.88) 3.10 (0.50)
12 2.89 (0.76) 2.53 (0.60)
13 2.83 (0.70) 3.10* (na)
14 2.99 (1.10) -
15 3.32 (0.25) 1.95* (na)
*n=1 for these age groups
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The effectiveness of stimulant medications is well-
documented in numerous published studies. The dilemma of 
growth suppression effects of stimulants has been debated in 
the literature since the early 1970s. Our study was designed 
to answer the question about possible growth-suppressant 
effects of stimulant treatment in children with ADHD. Our 
study included patients who took stimulant medications for 
at least 12 months, but they had stable growth velocities for 
considerably longer periods. Our decision not to subgroup 
these children (e.g., by stimulant types or dosages) could be 
considered a limitation of the study. A detailed study that 
examines growth velocities in children grouped by type and 
dosage of stimulant medication would add to the body of 
knowledge on this subject.
CONCLUSION
Compared with the general pediatric population, there 
were no significant differences in growth velocities 
among children taking various types or doses of stimulant 
medications. Our study results are reassuring and encourage 
us to continue prescribing stimulant medications for children 
with ADHD.
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Figure 1: Growth velocities of 62 female study participants 
in observed percentile levels, using the Fels Longitudinal 
study as a reference set. A majority (n = 44, 70.97%) of 
study participants recorded growth velocities at or below 
the 50th percentile for their age
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Figure 2: Growth velocities of 218 male study participants 
in observed percentile levels, using the Fels Longitudinal 
study as a reference set. A majority (n = 164, 75.23%) of 
study participants recorded growth velocities at or below 
the 50th percentile for their age
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